Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega-scale single cell analysis with improved efficiency and ease of use.

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

At this time, I would like to welcome everyone to the 10X Genomics fourth quarter and full year 2024 earnings conference call. (Operator Instructions). I would now like to turn the conference over to ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will ...

Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq ... archived and available for replay for at least 45 days after the event.

Find earnings, economic, stock splits and IPO calendars to track upcoming financial events from Yahoo Finance.

GeneDx , a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 45th Annual TD Cowen Health Care Conference from ...

This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...